Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many core labeling statements (mechanism, indications, several efficacy outcomes, contraindication, pancreatitis, hypoglycemia with insulin secretagogues/insulin, and several common AEs) are supported, but multiple substantial claims are unsupported or off-label (appetite/fullness, NASH/PCOS, exploratory off-label uses) and one claim has a likely label mismatch for duration (weight loss over 26 weeks).
Category Scores
Accurate Statements
Ozempic (semaglutide) is a GLP-1 receptor agonist.
11 DESCRIPTION; 12.1 Mechanism of Action
Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
1 INDICATIONS AND USAGE
Ozempic is approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
1 INDICATIONS AND USAGE
Ozempic is approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
1 INDICATIONS AND USAGE
Ozempic delays gastric emptying.
12.1 Mechanism of Action; 12.2 Pharmacodynamics
Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
4 CONTRAINDICATIONS; WARNING: RISK OF THYROID C-CELL TUMORS
Ozempic is associated with an increased risk of thyroid C-cell tumors.
WARNING: RISK OF THYROID C-CELL TUMORS (rodents; human unknown)
Ozempic is associated with an increased risk of pancreatitis (acute pancreatitis).
5.2 Acute Pancreatitis
Ozempic can cause hypoglycemia when used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin.
5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin; 7.1 Concomitant Use with an Insulin Secretagogue or with Insulin
Common side effects include nausea and vomiting.
6.1 Clinical Trials Experience (Table 1: Nausea; Vomiting)
Common side effects include diarrhea.
6.1 Clinical Trials Experience (Table 1: Diarrhea)
Common side effects include abdominal pain.
6.1 Clinical Trials Experience (Table 1: Abdominal pain)
Common side effects include injection site reactions.
6.1 Clinical Trials Experience (Injection Site Reactions)
Unsupported Statements
Ozempic reduces appetite.
No support in the supplied label sections.
Ozempic increases feelings of fullness.
No support in the supplied label sections.
Ozempic results in significant weight loss in patients with type 2 diabetes over 26 weeks.
Supplied label text describes weight/body-weight reductions but does not provide a 26-week-specific statement; durations shown include 30/56/40 weeks.
Ozempic improves liver function in patients with non-alcoholic steatohepatitis (NASH).
No support in the supplied label sections.
Ozempic reduces liver inflammation in patients with NASH.
No support in the supplied label sections.
Ozempic results in significant improvements in liver enzymes in patients with NASH.
No support in the supplied label sections.
Ozempic results in significant improvements in liver histology in patients with NASH.
No support in the supplied label sections.
Ozempic improves insulin sensitivity in patients with polycystic ovary syndrome (PCOS).
No support in the supplied label sections.
Ozempic reduces androgen levels in patients with PCOS.
No support in the supplied label sections.
Ozempic has been explored as a potential off-label use for gastric bypass surgery, improving weight loss and glycemic control.
No support in the supplied label sections; described as exploratory off-label use.
Ozempic has been explored as a potential off-label use for binge eating disorder, reducing binge eating episodes and improving weight loss.
No support in the supplied label sections; described as exploratory off-label use.
Ozempic has been explored as a potential off-label use for Prader-Willi syndrome, improving weight loss and glycemic control.
No support in the supplied label sections; described as exploratory off-label use.
Contradictions
Low
AI Statement
Ozempic is contraindicated in patients with thyroid C-cell tumors.
Label Reference
4 CONTRAINDICATIONS; WARNING: RISK OF THYROID C-CELL TUMORS specifies contraindication for personal/family history of MTC or MEN 2, and serious hypersensitivity.
Important Omissions
The provided claim set does not include dosing/administration details that are present in the label (initiation and maintenance doses, injection frequency, and maximum dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported efficacy claims for NASH/PCOS and appetite/fullness, plus off-label exploratory uses, could mislead use; however, major safety label items included (MTC/MEN 2 contraindication, thyroid C-cell tumor warning context, acute pancreatitis warning, and hypoglycemia risk with insulin secretagogues/insulin).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple unsupported or off-label exploratory claims (appetite/fullness; NASH/PCOS; gastric bypass/binge eating disorder/Prader-Willi) and a likely duration mismatch for weight-loss timing (26 weeks).
Suggested Improvement
Restrict statements to label-supported claims in the supplied sections; remove or rephrase unsupported appetite/fullness, NASH/PCOS, and off-label exploratory use assertions, and align weight-loss timing with label-specified trial durations.